Voter sentiment on California's Proposition 38 remains closely balanced ahead of the November 2026 ballot, with trader pricing reflecting skepticism toward the $8.4 billion general obligation bond for immunology and immunotherapy research. The measure would allocate roughly half the proceeds to a single UC-affiliated institute meeting narrow eligibility criteria—widely viewed as benefiting the California Institute for Immunology and Immunotherapy, backed by its billionaire co-founder—while directing the rest through competitive grants focused on cancer, heart disease, and Alzheimer's. Opposition centers on long-term General Fund repayment obligations, limited administrative oversight, and perceptions of targeted earmarking, echoing debates over prior biomedical bond measures. Support stems from arguments for dedicated state investment in medical research amid uncertain federal priorities, though recent reporting on the initiative's design has amplified concerns about institutional favoritism and fiscal impact without shifting the narrow edge against passage.
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jourProposition d'obligation de recherche en immunologie en Californie
Proposition d'obligation de recherche en immunologie en Californie
Oui
54% chance
NOUVEAU
NOUVEAU
3 nov. 2026
Oui
54% chance
NOUVEAU
NOUVEAU
3 nov. 2026
Proposition 38 is a California ballot measure currently scheduled for voting on November 3, 2026. It would allow the state to borrow $8.4 billion in debt to research immune system-based technologies for treating conditions including cancer, heart disease and Alzheimer’s.
This market will resolve to “Yes” if the specified ballot measure is approved by a majority of voters at the California statewide general election currently scheduled for November 3, 2026. Otherwise, this market will resolve to “No.”
If voting on the specified ballot measure does not occur, or the results thereof are not known definitively, by March 31, 2027, this market will resolve to “No”.
This market will resolve based on a consensus of credible reporting. If there is ambiguity, this market will resolve solely based on official information from the State of California, including the California Secretary of State (https://www.sos.ca.gov/).Voter sentiment on California's Proposition 38 remains closely balanced ahead of the November 2026 ballot, with trader pricing reflecting skepticism toward the $8.4 billion general obligation bond for immunology and immunotherapy research. The measure would allocate roughly half the proceeds to a single UC-affiliated institute meeting narrow eligibility criteria—widely viewed as benefiting the California Institute for Immunology and Immunotherapy, backed by its billionaire co-founder—while directing the rest through competitive grants focused on cancer, heart disease, and Alzheimer's. Opposition centers on long-term General Fund repayment obligations, limited administrative oversight, and perceptions of targeted earmarking, echoing debates over prior biomedical bond measures. Support stems from arguments for dedicated state investment in medical research amid uncertain federal priorities, though recent reporting on the initiative's design has amplified concerns about institutional favoritism and fiscal impact without shifting the narrow edge against passage.
Proposition 38 is a California ballot measure currently scheduled for voting on November 3, 2026. It would allow the state to borrow $8.4 billion in debt to research immune system-based technologies for treating conditions including cancer, heart disease and Alzheimer’s.
This market will resolve to “Yes” if the specified ballot measure is approved by a majority of voters at the California statewide general election currently scheduled for November 3, 2026. Otherwise, this market will resolve to “No.”
If voting on the specified ballot measure does not occur, or the results thereof are not known definitively, by March 31, 2027, this market will resolve to “No”.
This market will resolve based on a consensus of credible reporting. If there is ambiguity, this market will resolve solely based on official information from the State of California, including the California Secretary of State (https://www.sos.ca.gov/).
This market will resolve to “Yes” if the specified ballot measure is approved by a majority of voters at the California statewide general election currently scheduled for November 3, 2026. Otherwise, this market will resolve to “No.”
If voting on the specified ballot measure does not occur, or the results thereof are not known definitively, by March 31, 2027, this market will resolve to “No”.
This market will resolve based on a consensus of credible reporting. If there is ambiguity, this market will resolve solely based on official information from the State of California, including the California Secretary of State (https://www.sos.ca.gov/).
Marché ouvert : Jul 1, 2026, 6:33 PM ET
Volume
$2,851Date de fin
3 nov. 2026Marché ouvert
Jul 1, 2026, 6:33 PM ETResolver
0x65070BE91...Proposition 38 is a California ballot measure currently scheduled for voting on November 3, 2026. It would allow the state to borrow $8.4 billion in debt to research immune system-based technologies for treating conditions including cancer, heart disease and Alzheimer’s.
This market will resolve to “Yes” if the specified ballot measure is approved by a majority of voters at the California statewide general election currently scheduled for November 3, 2026. Otherwise, this market will resolve to “No.”
If voting on the specified ballot measure does not occur, or the results thereof are not known definitively, by March 31, 2027, this market will resolve to “No”.
This market will resolve based on a consensus of credible reporting. If there is ambiguity, this market will resolve solely based on official information from the State of California, including the California Secretary of State (https://www.sos.ca.gov/).Voter sentiment on California's Proposition 38 remains closely balanced ahead of the November 2026 ballot, with trader pricing reflecting skepticism toward the $8.4 billion general obligation bond for immunology and immunotherapy research. The measure would allocate roughly half the proceeds to a single UC-affiliated institute meeting narrow eligibility criteria—widely viewed as benefiting the California Institute for Immunology and Immunotherapy, backed by its billionaire co-founder—while directing the rest through competitive grants focused on cancer, heart disease, and Alzheimer's. Opposition centers on long-term General Fund repayment obligations, limited administrative oversight, and perceptions of targeted earmarking, echoing debates over prior biomedical bond measures. Support stems from arguments for dedicated state investment in medical research amid uncertain federal priorities, though recent reporting on the initiative's design has amplified concerns about institutional favoritism and fiscal impact without shifting the narrow edge against passage.
Proposition 38 is a California ballot measure currently scheduled for voting on November 3, 2026. It would allow the state to borrow $8.4 billion in debt to research immune system-based technologies for treating conditions including cancer, heart disease and Alzheimer’s.
This market will resolve to “Yes” if the specified ballot measure is approved by a majority of voters at the California statewide general election currently scheduled for November 3, 2026. Otherwise, this market will resolve to “No.”
If voting on the specified ballot measure does not occur, or the results thereof are not known definitively, by March 31, 2027, this market will resolve to “No”.
This market will resolve based on a consensus of credible reporting. If there is ambiguity, this market will resolve solely based on official information from the State of California, including the California Secretary of State (https://www.sos.ca.gov/).
This market will resolve to “Yes” if the specified ballot measure is approved by a majority of voters at the California statewide general election currently scheduled for November 3, 2026. Otherwise, this market will resolve to “No.”
If voting on the specified ballot measure does not occur, or the results thereof are not known definitively, by March 31, 2027, this market will resolve to “No”.
This market will resolve based on a consensus of credible reporting. If there is ambiguity, this market will resolve solely based on official information from the State of California, including the California Secretary of State (https://www.sos.ca.gov/).
Volume
$2,851Date de fin
3 nov. 2026Marché ouvert
Jul 1, 2026, 6:33 PM ETResolver
0x65070BE91...Voter sentiment on California's Proposition 38 remains closely balanced ahead of the November 2026 ballot, with trader pricing reflecting skepticism toward the $8.4 billion general obligation bond for immunology and immunotherapy research. The measure would allocate roughly half the proceeds to a single UC-affiliated institute meeting narrow eligibility criteria—widely viewed as benefiting the California Institute for Immunology and Immunotherapy, backed by its billionaire co-founder—while directing the rest through competitive grants focused on cancer, heart disease, and Alzheimer's. Opposition centers on long-term General Fund repayment obligations, limited administrative oversight, and perceptions of targeted earmarking, echoing debates over prior biomedical bond measures. Support stems from arguments for dedicated state investment in medical research amid uncertain federal priorities, though recent reporting on the initiative's design has amplified concerns about institutional favoritism and fiscal impact without shifting the narrow edge against passage.
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jour
Méfiez-vous des liens externes.
Méfiez-vous des liens externes.
Questions fréquentes